Related Experiment Videos
Extrahepatic cell membrane lipid abnormalities and cellular dysfunction in liver disease.
1Academic Department of Medicine, Royal Free Hospital School of Medicine, London, United Kingdom.
Drugs
|January 1, 1990
Summary
Liver disease alters circulating lipoproteins, impacting cell membranes and causing dysfunction. Therapies like S-adenosyl-L-methionine (SAMe) may improve cell function by fluidizing membranes.
Area of Science:
- Biochemistry
- Cell Biology
- Hepatology
Background:
- Liver disease causes significant alterations in plasma lipoprotein lipid composition.
- Decreased lecithin-cholesterol acyltransferase activity leads to cholesterol and lecithin accumulation in lipoproteins.
- Reduced arachidonate content in lipoproteins impacts eicosanoid production.
Purpose of the Study:
- To investigate the impact of altered lipoproteins on extrahepatic cell membrane composition and function in liver disease.
- To explore the hypothesis that lipoprotein-induced membrane changes contribute to cellular dysfunction in liver disease.
- To identify potential therapeutic strategies targeting membrane fluidity.
Main Methods:
- Analysis of lipid composition in plasma lipoproteins and cell membranes in human and experimental liver disease models.
- Assessment of cell membrane fluidity and protein function in affected tissues.
- Evaluation of the effects of membrane-fluidizing agents on cellular dysfunction.
Main Results:
- Confirmed widespread changes in cell membrane lipid composition mirroring those in circulating lipoproteins.
- Demonstrated that cholesterol enrichment of biomembranes reduces lipid fluidity, impairing membrane protein function.
- Observed that extrahepatic membrane dysfunction is a common feature of severe liver disease.
Conclusions:
- Lipoprotein-induced alterations in cell membrane lipid composition and fluidity are a key mechanism contributing to cellular dysfunction in liver disease.
- This mechanism suggests that impaired membrane function exacerbates metabolic abnormalities associated with hepatic disease.
- Agents that enhance membrane fluidity, such as S-adenosyl-L-methionine (SAMe), show potential for ameliorating cellular dysfunction in liver disease.